ELLIPSS: ELucidating the Landscape of Immunoendotypes in Psoriatic Skin and Synovium

ELLIPSS：阐明银屑病皮肤和滑膜的免疫内型概况

• 批准号: 10595620
• 负责人: Johann Eli Gudjonsson
• 金额: $ 160万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-21 至 2026-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10595620
• 关键词: Acceleration; Advertising; Affect; Aftercare; Autoimmune; Award; Bioinformatics; Biopsy; Blood; Cell Communication; Cells; Chronic small plaque psoriasis; Clinical Data; Clinical Protocols; Cohort Studies; Collaborations; Collection; Common Data Element; Communication; Consult; Coupled; Cues; Data; Data Collection; Dermatologist; Development; Disease; Disease Pathway; Elderly; Electronic Health Record; Enrollment; Exclusion Criteria; Fostering; Funding Opportunities; Genetic; Goals; Human Resources; Immune; Immunologics; Immunologist; Immunology; Individual; Inflammation; Joints; Knowledge; Knowledge Portal; Leadership; Link; Lupus; Manuscripts; Measures; Mediating; Medicine; Michigan; Molecular; Molecular Analysis; Molecular Profiling; Participant; Pathogenicity; Pathologist; Pathology; Patient Recruitments; Patient-Focused Outcomes; Patients; Personnel Management; Phenotype; Physicians; Pilot Projects; Proteomics; Protocols documentation; Psoriasis; Psoriatic Arthritis; Quality Control; Research Personnel; Resolution; Rheumatoid Arthritis; Sampling; Science; Scientist; Site; Skin; Standardization; Structure; Synovial Membrane; Systemic Lupus Erythematosus; Systems Biology; Technology; Testing; Tissue Banks; Tissue Sample; Tissues; Training; United States; Universities; Work; biomarker identification; cell type; chronic pain; clinical phenotype; clinically relevant; cohort; data sharing; disease phenotype; ethnic diversity; gut microbiome; improved; improved outcome; joint inflammation; joint injury; lipidomics; loss of function; microbial; microbiome; multidisciplinary; multiple omics; new therapeutic target; oral microbiome; participant enrollment; phenotypic data; programs; racial diversity; recruit; repository; rheumatologist; sample collection; scale up; skin microbiome; statistics; success; synergism; tissue processing; transcriptomics; treatment response

ABSTRACT Psoriatic Spectrum Diseases (PSD) affect over 8 million individuals in the U.S. living with psoriasis (PsO) or psoriatic arthritis (PsA) and encompass heterogeneous phenotypes of disease, ranging from plaque, guttate, palmoplantar, inverse, pustular, and erythrodermic forms of psoriasis, to synovial, enthesial, and axial forms of PsA. Here, we assembled a world class multidisciplinary team of scientists in PSD cohort assembly, clinical phenotyping, biosample acquisition, pathology, statistics, and bioinformatics, for the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) PSD Disease Teams (DTs). The major scientific goals of the PSD DT are to understand the cellular and molecular composition of distinct PSD endotypes and how they link with phenotypes, to identify how key pathogenic or regulatory cells spatially interact with each other and with environmental cues (i.e., microbiome), and to define at a single-cell level how the transition to PsA unfolds in the setting of PsO. To accomplish the goals of the PSD AMP, we propose the creation of the ELLIPSS (ELucidating the Landscape of Immunoendotypes in Psoriatic Skin and Synovium) Disease Team (DT). The AIMS of the ELLIPSS Team are to 1) to enroll diverse PSD cohorts and perform clinical phenotyping, data capture, and tissue collection. 2) to implement an effective management plan for the ELLIPSS multidisciplinary team. 3) to optimize interface of ELLIPSS team with AMP-AIM network. Lastly, a robust Opportunities Fund (OF) management program is proposed under the direction and leadership of Dr. James T. Elder at University of Michigan. The ELLIPSS PSD DT will efficiently integrate with the AMP AIM Network, facilitate collection of PSD biosamples, and help provide an unprecedented view of cell types and states, along with spatial and tissue interactions (skin, joint, blood, microbiome) to deconstruct/reconstruct the psoriatic disease spectrum.

摘要 银屑病谱系疾病(PSD)在美国影响着800多万患有银屑病(PSO)或 银屑病关节炎(PSA)包括不同的疾病表型，从斑块，点滴状， 掌足型、逆型、脓疱型和红皮型银屑病，滑膜型、末端型和轴型 PSA。在这里，我们聚集了一支世界级的多学科科学家团队，在PSD临床队列组装中 表型分析、生物样本采集、病理学、统计学和生物信息学 伙伴关系自身免疫和免疫介导性疾病(AMP AIM)PSD疾病小组(DT)。 PSD DT的主要科学目标是了解不同的细胞和分子组成 PSD内型及其与表型的联系，以确定关键的致病细胞或调控细胞如何在空间上 相互作用并与环境线索(即微生物组)相互作用，并在单细胞水平上定义 向PSA的过渡是在PSO的背景下展开的。为达致私营机构营运基金的目标，我们建议 ELLIPSS的建立(阐明银屑病患者皮肤和滑膜的免疫内分泌情况) 疾病小组(DT)。ELLIPSS团队的目标是1)招募不同的PSD队列并进行临床 表型鉴定、数据采集和组织收集。2)为ELLIPSS实施有效的管理计划 多学科团队。3)优化ELLIPSS团队与AMP-AIM网络的接口。最后，一个健壮的 机会基金(OF)管理计划是在James T.博士的指导和领导下提出的。 密歇根大学的大四学生。 ELLIPSS PSD DT将有效地与AMP AIM网络集成，促进PSD生物样本的收集， 并有助于提供对细胞类型和状态以及空间和组织相互作用(皮肤、 关节、血液、微生物组)来解构/重建银屑病病谱。